Researcher Profiles

Return to member profile

Janice M. Mehnert, MD

Publications since 2011

Teh, J. L. Shah, R. Shin, S. S. Wen, Y. Mehnert, J. M. Goydos, J. Chen, S. Metabotropic glutamate receptor 1 (mGluR1) mediates melanocyte transformation via transactivation of IGF-1 Receptor. Pigment Cell Melanoma Res, 27:621-629, . (PMID: 24628914, PMCID: PMC4061214)

Wen, Y. Y. Li, J. Koo, J. Shin, S. S. Lin, Y. Jeong, B. S. Mehnert, J. M. Chen, S. Cohen-Solal, K. Goydos, J. S. Activation of the Glutamate Receptor GRM1 Enhances Angiogenic Signaling to Drive Melanoma Progression. Cancer Res, 74:2499-2509, . (PMID: 24491800, PMCID: PMC4008638)

Salgia, R. Patel, P. Bothos, J. Yu, W. Eppler, S. Hegde, P. Bai, S. Kaur, S. Nijem, I. Catenacci, D. V. Peterson, A. Ratain, M. J. Polite, B. Mehnert, J. M. Moss, R. A. Phase I Dose-Escalation Study of Onartuzumab as a Single Agent and in Combination with Bevacizumab in Patients with Advanced Solid Malignancies. Clin Cancer Res, 20:1666-1675, . (PMID: 24493831)

Palyca, P. Koshenkov, V. P. Mehnert, J. M. Developments in the treatment of locally advanced and metastatic squamous cell carcinoma of the skin: a rising unmet need. Am Soc Clin Oncol Educ Book, :e397-e404, . (PMID: 24857130)

Ravi, S. Spencer, K. Ruisi, M. Ibrahim, N. Luke, J. J. Thompson, J. A. Shirai, K. Lawson, D. Bartell, H. Kudchadkar, R. Gunter, N. T. Mehnert, J. M. Lipson, E. J. Ipilimumab administration for advanced melanoma in patients with pre-existing Hepatitis B or C infection: a multicenter, retrospective case series. J Immunother Cancer, 2:33, . (PMID: 25317333, PMCID: PMC4195895)

Sharma, A. Thompson, J. A. Repaka, A. Mehnert, J. M. Ipilimumab administration in patients with advanced melanoma and hepatitis B and C. J Clin Oncol, 31:e370-e372, . (PMID: 23775956)

Xie, X. White, E. P. Mehnert, J. M. Coordinate Autophagy and mTOR Pathway Inhibition Enhances Cell Death in Melanoma. PLoS One, 8:e55096, . (PMID: 23383069, PMCID: PMC3559441)

Mehnert, J. M. Kluger, H. M. Driver Mutations in Melanoma: Lessons Learned From Bench-to-Bedside Studies. Curr Oncol Rep, 14:449-457, . (PMID: 22723080)

Saraiya, B. Chugh, R. Karantza, V. Mehnert, J. Moss, R. A. Savkina, N. Stein, M. N. Baker, L. H. Chenevert, T. Poplin, E. A. Phase I study of gemcitabine, docetaxel and imatinib in refractory and relapsed solid tumors. Invest New Drugs, 30:258-265, . (PMID: 20697775)

Mehnert, J. M. Tan, A. R. Moss, R. Poplin, E. Stein, M. N. Sovak, M. Levinson, K. Lin, H. Kane, M. Gounder, M. Lin, Y. Shih, W. J. White, E. Rubin, E. H. Karantza, V. Rationally designed treatment for solid tumors with MAPK pathway activation: a phase I study of paclitaxel and bortezomib using an adaptive dose-finding approach. Mol Cancer Ther, 10:1509-1519, . (PMID: 21680752, PMCID: PMC3155243)

Khan, A. J. Wall, B. Ahlawat, S. Green, C. Schiff, D. Mehnert, J. M. Goydos, J. S. Chen, S. Haffty, B. G. Riluzole Enhances Ionizing Radiation-Induced Cytotoxicity in Human Melanoma Cells that Ectopically Express Metabotropic Glutamate Receptor 1 In Vitro and In Vivo. Clin Cancer Res, 17:1807-1814, . (PMID: 21325066, PMCID: PMC3070864)